Evidence mapPaperPMID 39479608Full record

ReviewFood science & nutrition2024

Mangiferin: An effective agent against human malignancies.

Nimra Irshad, Hammad Naeem, Muhammad Shahbaz, Muhammad Imran, Ahmed Mujtaba, Muzzamal Hussain, Waleed Al Abdulmonem, Suliman A Alsagaby, Tadesse Fenta Yehuala, Mohamed A Abdelgawad and 4 more

Abstract readReview
In one paragraph

Review in Food science & nutrition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. ANKRD1 expression and functional mechanism in stomach adenocarcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Nimra IrshadDepartment of Food Science and Technology Muhammad Nawaz Shareef University of Agriculture, Multan Multan Pakistan.
Hammad NaeemDepartment of Food Science and Technology Muhammad Nawaz Shareef University of Agriculture, Multan Multan Pakistan.
Muhammad ShahbazDepartment of Food Science and Technology Muhammad Nawaz Shareef University of Agriculture, Multan Multan Pakistan.
Muhammad ImranDepartment of Food Science and Technology University of Narowal Narowal Pakistan.
Ahmed MujtabaDepartment of Food Sciences and Technology, Faculty of Engineering Sciences and Technology Hamdard University Islamabad Campus Islamabad Pakistan.
Muzzamal HussainDepartment of Food Sciences Government College University Faisalabad Faisalabad Pakistan.ORCID https://orcid.org/0000-0001-6508-1962
Waleed Al AbdulmonemDepartment of Pathology, College of Medicine Qassim University Buraidah Saudi Arabia.
Suliman A AlsagabyDepartment of Medical Laboratory Sciences, College of Applied Medical Sciences Majmaah University AL-Majmaah Saudi Arabia.
Tadesse Fenta YehualaFaculty of Chemical and Food Engineering, Bahir Dar Institute of Technology Bahir Dar University Bahir dar Ethiopia.ORCID https://orcid.org/0000-0001-9241-0266
Mohamed A AbdelgawadDepartment of Pharmaceutical Chemistry, College of Pharmacy Jouf University Sakaka Aljouf Saudi Arabia.
Mohammed M GhoneimDepartment of Pharmacy Practice, College of Pharmacy AlMaarefa University Ad Diriyah Riyadh Saudi Arabia.
Ehab M MostafaDepartment of Pharmacognosy, College of Pharmacy Jouf University Sakaka Saudi Arabia.
Samy SelimDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences Jouf University Sakaka Saudi Arabia.ORCID https://orcid.org/0000-0003-4025-8586
Soad K Al JaouniDepartment of Hematology/Oncology, Yousef Abdulatif Jameel Scientific Chair of Prophetic Medicine Application, Faculty of Medicine King Abdulaziz University Jeddah Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mangiferin is a bioactive substance present in high concentration in mangoes and also in some other fruits. Owing to its potential as a chemopreventive and chemotherapeutic agent against several types of cancer, this unique, significant, and well-researched polyphenol has received a lot of attention recently. It possesses the ability to treat cancers, including rectal cancer, prostate cancer, ovarian cancer, leukemia, gastric cancer, liver cancer, chronic pancreatitis, and lung cancer. It can control/regulate multiple key signaling pathways, such as signal transducer and activator of transcription 3 (STAT3), second mitochondria-derived activator of caspases/direct inhibitor of apoptosis (IAP)-binding protein with low propidium iodide (pl) (Smac/DIABLO) nuclear factor kappa B (NF-κB), phosphatidylinositol 3 kinase/protein 3 kinase (PI3K/Akt), transforming growth factor beta/suppressor of mothers against decapentaplegic (TGF-β/SMAD), c-jun N-terminal kinase/p38 mitogen-activated protein kinase (JNK/p38-MAPK), and phosphor-I kappa B kinase (p-IκB), which are crucial to the development of cancers. By triggering apoptotic signals and halting the advancement of the cell cycle, it can also prevent some cancer cell types from proliferating and developing. It has been revealed that mangiferin targets a variety of adhesion molecules, cytokines, pro-inflammatory transcription factors, kinases, chemokines, growth factors, and cell-cycle proteins. By means of preventing the onset, advancement, and metastasis of cancer, these targets may mediate the chemopreventive and therapeutic effects of mangiferin. Mangiferin has confirmed potential benefits in lung, cervical, breast, brain, and prostate cancers as well as leukemia whether administered alone or in combination with recognized anticancer compounds. More clinical trials and research investigations are required to completely unleash the potential of mangiferin, which may lower the risk of cancer onset and act as a preventive and therapeutic alternative for a number of cancers.

Indexed as

anticancerbioactive compoundchemopreventivechronic pancreatitismangiferintherapeutic alternative

Identifiers

PMID39479608
PMCPMC11521646

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.